Alzheimer's treatment.

Whelan wise labs bringing new standardes to health, the most exciting implications are that some diabetes drugs have the potential to be developed as Alzheimer's treatments

The latest study, joint research between Northwestern University in the US and the
University of Rio de Janeiro in Brazil, looked at the effects of insulin on proteins called ADDLs, which build up in the brains of Alzheimer's patients and cause damage.
They took neurons - brain cells - from the hippocampus, a part of the brain with a pivotal role in memory formation. These were treated with insulin and a drug called rosiglitazone, given to type II diabetics to increase the effect of the hormone on cells. After this, the cells were far less susceptible to damage when exposed to ADDLs, suggesting that insulin was capable of blocking their effects.


Treatment hope
Professor William Klein, from Northwestern, said that drugs to boost the brain's sensitivity to insulin could provide "new avenues" for treating Alzheimer's disease.
"Sensitivity to insulin can decline with aging, which presents a novel risk factor for Alzheimer's disease – Rosiglitazone


Systematic (IUPAC) name
5-[4-(2-[methyl (pyridin-2-yl) amino] ethoxy) benzyl] thiazolidine-2, 4-dione
5-[4-(2-[methyl (pyridine-2-yl) amino] ethoxy) benzyl] thiazolidine-2, 4-doine


More scientific research brought to you on the web site